Skip to content
For laboratory research use only · Not for human or veterinary use · Qualified buyers only
Peptides

What Is Retatrutide? Triple-Receptor Agonist Identity and Laboratory Documentation

A research-use identity note on retatrutide as a triple glucagon/GIP/GLP-1 agonist, with attributed published findings and lot documentation.

What Is Retatrutide? Triple-Receptor Agonist Identity and Laboratory Documentation

Retatrutide is an investigational peptide designed to engage GIP, GLP-1, and glucagon receptors in metabolic-signaling research. The original overview of this page asks three questions: triple-receptor agonist design, receptor-specific assay interpretation, and identity, purity, content, and aggregation testing.

Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.

Triple-receptor agonist design

Coskun and colleagues described LY3437943 as a novel triple agonist peptide at the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R). In the in-vitro characterization they reported, LY3437943 showed balanced GCGR and GLP-1R activity and relatively greater GIPR activity (Coskun et al., 2022). Jastreboff and colleagues identified retatrutide (LY3437943) as an agonist of the GIP, GLP-1, and glucagon receptors in a phase 2 obesity trial (Jastreboff et al., 2023). That receptor set is not the same as tirzepatide’s dual GIP/GLP-1 design or semaglutide’s selective GLP-1-analogue identity. See Tirzepatide: Dual GIP/GLP-1 Agonist Identity and Laboratory Documentation, Semaglutide: GLP-1-Analogue Identity, Sequence Modifications, and Laboratory Documentation, and Retatrutide vs Tirzepatide.

Assays that read out one receptor should not be filed as if they documented the other two. The brief should name retatrutide, not a generic “incretin agonist.”

Published clinical-research observations — and their limits

Jastreboff and colleagues conducted a phase 2, double-blind, randomized, placebo-controlled trial in 338 adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. They reported larger least-squares mean percentage reductions in body weight with retatrutide than with placebo at 24 weeks and at 48 weeks, across the dose groups they studied (Jastreboff et al., 2023). Those percentages belong to that phase 2 design. They are not a protocol, they do not provide administration guidance, and they do not describe a current catalog lot.

The phase 2 time points and the receptor-balance description in Coskun et al. (2022) should stay attached to retatrutide. They do not complete a tirzepatide or semaglutide file, and they do not authorize reading a single-receptor assay as if it represented the full triple-agonist profile. A later head-to-head comparison, if one is published, would still need to be read in its own design; it would not replace lot-level identity documents.

Identity, purity, content, and aggregation

A useful quality review still separates analogue identity, purity, content, and aggregation. What Is a Peptide COA?, How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, Third-Party Peptide Testing, Explained, and lot traceability apply independently to this row.

Retatrutide appears in Velnacor’s research-material catalog (internal product record, slug retatrutide), as does a combination SKU with tirzepatide. There is not a standalone public landing page for every catalog name; use the product directory and the COA Library, then confirm the exact SKU and current-lot documents in the inquiry. Combination presentations, if purchased, need their own identifiers. For packing at supply scale, see wholesale peptides.

Selected published literature

  1. Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O’Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013. PubMed 35985340.
  2. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972. PubMed 37366315. Cited as published clinical-research observations, not as a use instruction.

Sourcing notes for qualified buyers

Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.

Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.

Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.

My inquiry listNo products added yet0